Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure - Wikidata - wikimedia - TriplyDB

Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure

Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure

http://www.wikidata.org/entity/Q24684669

about

Transient receptor potential (TRP) channels and cardiac fibrosis Prediction of atrial fibrillation development and progression: Current perspectives Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition.Atrial Electrophysiological Remodeling and Fibrillation in Heart Failure Neural substrate of posterior left atrium: A novel modulation for inducibility and remodeling of atrial fibrillation in canine Transmural characteristics of atrial fibrillation in canine models of structural and electrical atrial remodeling assessed by simultaneous epicardial and endocardial mapping Recent advances in pharmacotherapy of atrial fibrillation In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion.The expression levels of plasma micoRNAs in atrial fibrillation patients.Anti-fibrotic action of pirfenidone in Dupuytren's disease-derived fibroblasts Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation.Atrial fibrosis and the mechanisms of atrial fibrillation Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1.Cardiac fibrosis as a determinant of ventricular tachyarrhythmias.TheTGFB1 functional polymorphism rs1800469 and susceptibility to atrial fibrillation in two Chinese Han populations.Inflammatory cytokines and atrial fibrillation: current and prospective views The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts Fibrosis in Atrial Fibrillation - Role of Reactive Species and MPO.Serum and tissue biomarkers in aortic stenosis.The Use of Gene Therapy for Ablation of Atrial Fibrillation.Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin Circulating Biomarkers Predictive of Postoperative Atrial Fibrillation.Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts.Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.Atrial fibrillation begets atrial fibrillation: autonomic mechanism for atrial electrical remodeling induced by short-term rapid atrial pacing.Role of TGF-beta on cardiac structural and electrical remodeling.Mechanisms with clinical implications for atrial fibrillation-associated remodeling: cathepsin K expression, regulation, and therapeutic target and biomarker.Association of TGFBR2 polymorphism with risk of sudden cardiac arrest in patients with coronary artery disease.Atrial Fibrillation and Heart Failure: A Review of the Intersection of Two Cardiac Epidemics.Structural and Functional Remodeling of the Left Atrium: Clinical and Therapeutic Implications for Atrial Fibrillation.Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure.Upstream therapy of atrial fibrillation.Atrial fibrillation: mechanisms, therapeutics, and future directions.Animal models for atrial fibrillation: clinical insights and scientific opportunities.Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.Atrial fibrillation-the final frontier.Mechanisms of termination and prevention of atrial fibrillation by drug therapy.Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β.

P2860

Q24625500-324FFC52-55E8-47A1-8416-B1CF264E6C67 Q26750083-8A7B176F-6B7D-48F5-A27D-4E5E69C8E72A Q26864767-D0BB4DA6-1407-4AF3-B9FE-C469E4DD5936 Q27302407-FA9F0EA8-8A93-4537-A79E-59940088245E Q28066307-046AD383-761E-4D23-B0D3-53DE2303F15E Q33642877-1791684F-7546-42F0-B354-8241C189739A Q33746539-D5B4E14B-313D-41B8-9EC8-70893E3A99FB Q33874035-4AF64404-F281-48D5-BBEE-D3B3D304980C Q34088175-9103F343-121E-43BC-83EB-C05AEA9BC448 Q34427635-300D61BE-548E-47C1-8A0D-C777112E3CA6 Q34544470-26C00E38-3961-47BB-B318-1F319457AD58 Q34575287-225D808B-7121-4C74-AD07-5D6D9BDEAE39 Q34576855-E5F3AA72-9D0C-4D00-B2FA-CFE8C9BE4236 Q34650822-0B19986E-32B6-46E7-A6FE-F9BBFACA634C Q35019379-1F7D8FC0-F463-44FE-9268-26830E2140D3 Q35070728-A349901A-AAEA-48AC-80EA-4B216C7849A5 Q35557385-B2E2E66E-B55D-4B4B-89EC-972420E2672E Q35943432-F4AEDF24-2942-4C7E-ACE7-CC72775E2422 Q36047754-A050E3FC-C8C3-452F-8A28-B52B4A5DC714 Q36457058-77ADF9E0-B622-4870-8F0B-A1F323FBDF3D Q36458906-81337AE8-547A-45F2-8DDF-D8999638C0A2 Q37071681-A9A2EDF6-48B8-45D4-A25C-753D8D5673C0 Q37094015-225EF00B-545C-4FBE-A5D3-C6A5B6D25254 Q37173939-39FE01F9-CF2D-46E8-BB90-159540AC19FD Q37305376-93A5FA55-1743-4E64-A285-26ED60BB83BC Q37398677-47B2CA27-45B1-47DB-B769-0B7CBBEC9A9E Q37428869-8614A1B1-084C-4193-8CF4-C044F54BDA2D Q37457719-A1B16C26-C5A8-4140-B5AD-D874F5EC3CAE Q37461361-129FED56-69FA-4DE3-8037-269BB00F1A1F Q37495775-2DEFD6FC-7D6E-4D95-ACBE-CFFF1A536271 Q37496071-3FC3916A-D046-4E12-982B-51676197C4B6 Q37496298-AC4EBCAA-9258-4A19-A38B-16420CD20F63 Q37546133-B49144EF-60D8-4E03-A646-21D133EE8D5F Q37590158-83AB546F-D0A1-4362-A56D-1FBE1A4694E1 Q37624219-47D98981-DC82-4EFB-BD64-1993F89D6BD4 Q37686160-11AB9BFC-1AB8-4EEE-8A42-D88869FE93E7 Q37708036-F57ECE63-B8CB-4571-98D2-F28315489D0F Q37799693-055A1C55-82AE-4B4F-94DD-A22037B024B9 Q37844891-F37A8904-4145-4192-A02D-03E03FFB5D0D Q37924999-147819C8-0F66-470C-BE14-561981CD312A

P2860

Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure

http://www.wikidata.org/entity/Q24684669

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Pirfenidone prevents the devel ...... canine model of heart failure

@ast

Pirfenidone prevents the devel ...... canine model of heart failure

@en

Pirfenidone prevents the devel ...... canine model of heart failure

@nl

type

label

Pirfenidone prevents the devel ...... canine model of heart failure

@ast

Pirfenidone prevents the devel ...... canine model of heart failure

@en

Pirfenidone prevents the devel ...... canine model of heart failure

@nl

prefLabel

Pirfenidone prevents the devel ...... canine model of heart failure

@ast

Pirfenidone prevents the devel ...... canine model of heart failure

@en

Pirfenidone prevents the devel ...... canine model of heart failure

@nl

P1433

Q24684669-1EA38FA1-F2FC-4D05-9E10-EF00E1567B3B

P1476

Q24684669-42A01D99-AAD8-46F4-BA27-F63CEEEE42A3

P2093

Q24684669-646807EB-3FAA-4405-BA00-01457C71CF9D

Q24684669-6CFC3621-252C-4DFC-9208-5D49E5E826BF

Q24684669-AEDF8422-5B7F-4BDF-BC0C-6ED134232057

Q24684669-CDEAEE63-0376-4A4C-8661-A299A7FD4015

Q24684669-D73EE0D1-0E0C-48BD-A1AE-5373E72D9895

Q24684669-DC0990EF-66F4-43B4-8457-24C96892E613

Q24684669-EDF4F22C-FFC2-47B1-9DD1-274D234FD59B

P2860

Q24684669-01FD266B-981B-4B9C-8B95-756C38CCD91C

Q24684669-133DA456-84D0-4EFA-A873-47DC9F21309B

Q24684669-2893ED48-BC56-4CE1-930C-40781C247DEB

Q24684669-2D388F01-6991-4C94-BBD8-64C46CB548F0

Q24684669-3357881E-8B41-4041-8FEE-E0ED1ED47EB7

Q24684669-39CA36C4-2EB4-41F3-83C2-91EC1496C7E7

Q24684669-58A4E738-3FAD-483D-87EA-DDFB23912B69

Q24684669-62F9932F-FFF4-4BF1-A8D7-320410779636

Q24684669-64C12A93-769D-4112-8A53-0F3EEC08DE23

Q24684669-6753744B-0072-4275-AEB3-195B8FF3847C

P304

Q24684669-0EAE5F1D-0EC2-4B76-9182-06187E3590B5

P31

Q24684669-51B0B310-D8E6-4BC8-8C8B-85A2322CF2A1

P3181

Q24684669-92D29100-DF26-43EA-90E9-6B15C55869C4

P356

Q24684669-FBF64489-0932-4955-AC86-510CB46C2703

P407

Q24684669-710C7D21-59BE-4CA8-982C-9E61426E6838

P433

Q24684669-0D783801-21F8-47BA-8A3E-DCB7E316B441

P478

Q24684669-0E276F83-C0AE-43EE-AEBA-A84A9A72F035

P577

Q24684669-55C1A787-96DD-42BC-AA5B-8D0DCA5F58EF

P5875

Q24684669-C4D014C0-0AEA-4F9C-827D-C3D74D793721

P698

Q24684669-92A9A904-E361-40E4-8D83-BF5DF9312FB6

P921

Q24684669-DE037360-624B-4205-812E-A7EB83030717

Q24684669-EA375D41-3561-4FE8-9B7E-AE254C3B7382

P932

Q24684669-06400130-1435-4C99-A90C-0641317B91FA

P3181

P356

CIRCULATIONAHA.106.624320

P1433

P1476

Pirfenidone prevents the devel ...... canine model of heart failure

@en

P2093

Chunhua Ding

http://www.w3.org/2001/XMLSchema#string

Dulkon Rahmutula

http://www.w3.org/2001/XMLSchema#string

Emily Wilson

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Olgin

http://www.w3.org/2001/XMLSchema#string

Jose M Guerra

http://www.w3.org/2001/XMLSchema#string

Ken W Lee

http://www.w3.org/2001/XMLSchema#string

Thomas H Everett

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4

Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats

Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats

Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat.

Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.

Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.

Pirfenidone effectively reverses experimental liver fibrosis.

Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters.

Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model.

Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective.

P304

1703-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2587929

http://www.w3.org/2001/XMLSchema#string

P356

10.1161/CIRCULATIONAHA.106.624320

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6763904

http://www.w3.org/2001/XMLSchema#string

P698

17030685

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

2129103

http://www.w3.org/2001/XMLSchema#string